Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 1Osteoporosis, Postmenopausal 1Neoplasms 1Endometrial Neoplasms 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × LY 353381 × Clear all
NCT00005879 2017-05-30

LY353381 in Preventing Breast Cancer in Women With Hyperplasia

University of Kansas Medical Center

Phase 2 Completed
199 enrolled 16 charts
Breast

Breast Neoplasms

NCT00190697 2007-05-25

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

Phase 4 Completed
70 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00034125 2006-07-19

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Eli Lilly and Company

Phase 3 Completed
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡